21.
Effect of Angiotensin-Converting Enzyme Inhibition on Survival in 3773 Chinese Type 2 Diabetic Patients
by So, Wing Yee
Hypertension (Dallas, Tex. 1979), 2004-09, Vol.44 (3), p.294-299
22.
23.
24.
Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: A brief overview of microalbuminuria and insulin resistance
by Mangrum, Amy
Journal of Diabetes and Its Complications, 1997, Vol.11 (6), p.352-357
25.
Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension
by BIGAZZI, R
American journal of hypertension, 1993, Vol.6 (2), p.108-113
26.
Clinical relevance of albuminuria in hypertensive patients
by Ritz, E.
The Clinical Investigator, 1992, Vol.70 (S2)
27.
A long-term follow-up study of japanese diabetic patients: mortality and causes of death
by SASAKI, A
Diabetologia, 1983, Vol.25 (4), p.309-312
28.
Albuminuria in chronic heart failure: prevalence and prognostic importance
by Jackson, Colette E, MB ChB
The Lancet (British edition), 2009, Vol.374 (9689), p.543-550
29.
Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease
by Lees, Jennifer S
Nature medicine, 2019-11, Vol.25 (11), p.1753-1760
30.
Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial
by Alborzi, Pooneh
Hypertension (Dallas, Tex. 1979), 2008-08, Vol.52 (2), p.249-255
31.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
by Xie, Xinfang, MD
The Lancet (British edition), 2016, Vol.387 (10017), p.435-443
32.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
by de Zeeuw, Dick, Prof
The Lancet (British edition), 2010, Vol.376 (9752), p.1543-1551
33.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis
by Mahmoodi, Bakhtawar K, MD
The Lancet (British edition), 2012, Vol.380 (9854), p.1649-1661
34.
Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study
by Jensen, Magnus T
Diabetologia, 2014-01-22, Vol.57 (4), p.672-680
35.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
by Gansevoort, Ron T, Dr
The Lancet (British edition), 2013-07-27, Vol.382 (9889), p.339-352
36.
Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus
by Min, Se Hee
Journal of diabetes and its complications, 2017-10, Vol.31 (10), p.1499-1505
37.
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
by Matsushita, Kunihiro
The Lancet (British edition), 2010, Vol.375 (9731), p.2073-2081
38.
Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes
by Wang, Hao-hua
Journal of diabetes and its complications, 2015, Vol.29 (3), p.384-389
39.
Relationships between electrochemical skin conductance and kidney disease in Type 2 diabetes
by Freedman, Barry I
Journal of diabetes and its complications, 2014, Vol.28 (1), p.56-60
40.
Blood Pressure Control Is Similar in Treated Hypertensive Patients With Optimal or With High-Normal Albuminuria
by Oliveras, Anna
American journal of hypertension, 2014-09-01, Vol.27 (9), p.1185-1190
